Results 111 to 120 of about 8,117 (271)

Biological and target synthetic treatments for chronic spontaneous urticaria: A systematic review and network meta‐analysis

Clinical and Translational Allergy, Volume 15, Issue 5, May 2025.
Abstract Background Most biological and synthetic target‐specific drugs for antihistamine‐refractory chronic spontaneous urticaria (CSU) have not been compared head‐to‐head. This systematic review and network meta‐analysis evaluated their relative efficacy and safety.
Zuotao Zhao, Yaqi Zheng, Xiaoting Song, Chengyue Peng, Shuanglu Liao, Peixin Zhang, Yen Tan, Xiaojie Huang, Litao Zhang   +8 more
wiley   +1 more source

Involvement of IL‐13‐Induced Dysregulation of BDNF‐NTRK2 Pathway in Symptoms of Eosinophilic Esophagitis

Allergy, EarlyView.
Kasumi Osonoi, Akinari Sawada, Yuki Maekawa, Mari Yamaguchi, Shingo Yamada, Kazuhiro Matsuyama, Mark Rochman, Marc E. Rothenberg, Xiaobo Han, Naoki Matsuda, Ikuro Suzuki, Fumio Tanaka, Yasuhiro Fujiwara, Tetsuo Shoda   +13 more
wiley   +1 more source

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series

Journal of Asthma and Allergy, 2021
Francesco Menzella,1 Marco Bonavia,2 Matteo Bonini,3 Maria D’Amato,4 Salvatore Lombardo,5 Nicola Murgia,6 Vincenzo Patella,7,8 Massimo Triggiani,9 Girolamo Pelaia10 1Pneumology Unit, Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia-IRCCS,
Menzella F, Bonavia M, Bonini M, D'Amato M, Lombardo S, Murgia N, Patella V, Triggiani M, Pelaia G   +8 more
doaj  

Targeting eosinophils: severe asthma and beyond [PDF]

, 2019
Recent research in the field of bronchial asthma has mainly focused on eosinophilic disease phenotype. Several trials proved the efficacy and safety profile of eosinophils and interleukin (IL)-5 targeting molecules, currently approved for severe asthma ...
Caminati, Marco, Guidolin, Lucia, Menzella, Francesco, Senna, Gianenrico   +3 more
core   +1 more source

Obesity: Next game changer of allergic airway diseases?

Clinical and Translational Medicine, Volume 15, Issue 5, May 2025.
Obesity affects various aspects of allergic airway diseases, including prevalence, endotypes, clinical features and therapeutic efficacy. Therefore, obesity‐related allergic airway diseases represent a unique class of endotypes and phenotypes, which need much more in‐depth research for tailored treatment.
Wenlong Li, Noah Marx, Qintai Yang, Deyu Fang, Yana Zhang   +4 more
wiley   +1 more source

Relapse of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Despite Maintenance Treatment With Low‐Dose Mepolizumab

Respirology Case Reports, Volume 13, Issue 5, May 2025.
We present the case of an ANCA+ EGPA patient with a long disease history and remission for over 8 years (between 2015 and 2023), who developed a life‐threatening relapse marked by diffuse alveolar haemorrhage and mononeuritis multiplex despite low‐dose mepolizumab (100 mg q4w) maintenance therapy.
Aurelie Vanthuyne, Sebastian Riemann, Guy Brusselle   +2 more
wiley   +1 more source

Geographic and economic influences on benralizumab prescribing for severe asthma in Japan

Scientific Reports
Benralizumab, a monoclonal antibody targeting IL-5 receptors, reduces exacerbations and oral corticosteroid requirements for severe, uncontrolled eosinophilic asthma.
Nobuaki Kobayashi, Hiromi Matsumoto, Kohei Somekawa, Ayami Kaneko, Nobuhiko Fukuda, Suguru Muraoka, Yukiko Ohtsu, Momo Hirata, Ryo Nagasawa, Sousuke Kubo, Kota Murohashi, Hiroaki Fujii, Ayako Aoki, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Takeshi Kaneko   +16 more
doaj   +1 more source

Early response to benralizumab in Canadian patients with severe eosinophilic asthma: Interim results from a prospective observational cohort

Canadian Journal of Respiratory Critical Care and Sleep Medicine
RATIONALE: There is a need to characterize the real-world impact of benralizumab, an anti-interleukin-5 receptor alpha antibody, for add-on maintenance therapy of patients with severe eosinophilic asthma.
S. Noorduyn, S. Kayaniyil, B. Lancaster, D. Dorscheid, O. Tourin, Brandie L. Walker, A. Thawer, Warren Ramesh, Irfan Khan, Harold Kim, Gordon Sussman, Lawrence Mbuagbaw, E. Penz   +12 more
semanticscholar   +1 more source

Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study) [PDF]

, 2021
Eva Martínez‐Moragón, Ismael García‐Moguel, Javier Nuevo, Gustavo Resler, I. Antépara, Ebymar Arismendi, Francisco Casas Maldonado, I. Dávila-González, Ismael García‐Moguel, José Luis Velasco-Garrido, Rocío Magdalena Díaz-Campos, Carmen Díaz-Donado, Beatriz G. Gálvez, José Luís Izquierdo Alonso, Antolín López-Viña, Eva Martínez‐Moragón, Cristina Navarro‐Soriano, Marta Palop-Cervera, Luis Pérez de Llano, Vicente Plaza, Miguel A. Racionero, Manuel J. Rial, Marina Carmen Rodríguez-Hernández, María Jesús Rodríguez‐Nieto, M.T. Martinez Zabaleta   +24 more
openalex   +1 more source

Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps

Allergy, Volume 80, Issue 5, Page 1208-1225, May 2025.
ABSTRACT Emerging biologics that selectively target key cytokines present a promising therapeutic alternative for patients suffering from severe, uncontrollable chronic rhinosinusitis with nasal polyps (CRSwNP). Despite the limited availability of registered biologics for CRSwNP treatment in China, the country is experiencing rapid development in this ...
Mu Xian, Bing Yan, Xicheng Song, Jianjun Chen, Jun Tang, Yan Jiang, Lijia Wan, Wen Liu, Jinmei Xue, Zhiwei Cao, Yafeng Yu, Xiangli Yang, Li Shi, Guangke Wang, Yu Xu, Yucheng Yang, Jing Ye, Luyun Jiang, Fang Quan, Guolin Tan, Feng Liu, Zhendong Xu, Xiaowen Zhang, Jiping Li, Lizhong Su, Yi Yang, Jiangang Fan, Gang He, Li Zhu, Xiangdong Wang, Ming Wang, Shen Shen, Jian Li, Huabin Li, Xin Wei, Hongmeng Yu, Zheng Liu, Ruixia Ma, Huanhai Liu, Jianfeng Liu, Wei Lv, Qintai Yang, Dongdong Zhu, Lei Cheng, Chengshuo Wang, Luo Zhang   +45 more
wiley   +1 more source